McKesson had previously filed a Class II recall voluntarily last March following the incident, and issued a corrective patch to 10 affected customers. In a statement, McKesson states no patient harm resulted from the incident, and the company is closely monitoring the software.
Class I is the FDA’s highest level of recall, used when there is “a situation in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death.” McKesson is currently working with the FDA to close the Class I recall.
More Articles on the FDA:
AHA Seeks FDA Action on Saline, IV Solution Shortage
FDA Approves Implantable Device for Certain Type of Hearing Loss
6 Senators Press for Clarity Over FDA Regulation of Health IT
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
